Galecto (GLTO) Competitors $4.70 +0.04 (+0.86%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GLTO vs. LPCN, PLUR, LVTX, NAII, ENLV, LSB, EQ, SNTI, AKTX, and CMMBShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Lipocine (LPCN), Pluri (PLUR), LAVA Therapeutics (LVTX), Natural Alternatives International (NAII), Enlivex Therapeutics (ENLV), Lakeshore Biopharma (LSB), Equillium (EQ), Senti Biosciences (SNTI), Akari Therapeutics (AKTX), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Galecto vs. Lipocine Pluri LAVA Therapeutics Natural Alternatives International Enlivex Therapeutics Lakeshore Biopharma Equillium Senti Biosciences Akari Therapeutics Chemomab Therapeutics Lipocine (NASDAQ:LPCN) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Is LPCN or GLTO more profitable? Lipocine's return on equity of -19.17% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -19.17% -17.60% Galecto N/A -76.96%-66.59% Which has more risk & volatility, LPCN or GLTO? Lipocine has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Which has better earnings and valuation, LPCN or GLTO? Lipocine has higher revenue and earnings than Galecto. Lipocine is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$7.92M3.29-$16.35M-$0.76-6.41GalectoN/AN/A-$38.35M-$19.14-0.25 Does the MarketBeat Community favor LPCN or GLTO? Lipocine received 315 more outperform votes than Galecto when rated by MarketBeat users. Likewise, 69.26% of users gave Lipocine an outperform vote while only 60.38% of users gave Galecto an outperform vote. CompanyUnderperformOutperformLipocineOutperform Votes34769.26% Underperform Votes15430.74% GalectoOutperform Votes3260.38% Underperform Votes2139.62% Do analysts prefer LPCN or GLTO? Lipocine presently has a consensus target price of $10.00, suggesting a potential upside of 105.34%. Galecto has a consensus target price of $10.00, suggesting a potential upside of 112.77%. Given Galecto's higher possible upside, analysts clearly believe Galecto is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in LPCN or GLTO? 9.1% of Lipocine shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 6.1% of Lipocine shares are held by insiders. Comparatively, 11.9% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor LPCN or GLTO? In the previous week, Lipocine had 6 more articles in the media than Galecto. MarketBeat recorded 6 mentions for Lipocine and 0 mentions for Galecto. Lipocine's average media sentiment score of 0.23 beat Galecto's score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Overall Sentiment Lipocine Neutral Galecto Neutral SummaryLipocine beats Galecto on 10 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.19M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.2510.5991.3417.19Price / SalesN/A195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.165.104.794.78Net Income-$38.35M$151.51M$120.07M$225.60M7 Day Performance-7.48%-2.15%-1.89%-1.24%1 Month Performance-19.59%-3.14%11.45%3.36%1 Year Performance-70.16%11.50%30.61%16.58% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto2.1612 of 5 stars$4.70+0.9%$10.00+112.8%-69.2%$6.19MN/A-0.2540LPCNLipocine1.5341 of 5 stars$4.97-1.0%$10.00+101.2%+63.4%$26.58M$7.92M-6.6110News CoveragePLURPluri0.4281 of 5 stars$4.71-0.2%N/A+10.5%$26.19M$330,000.000.00150News CoveragePositive NewsLVTXLAVA Therapeutics3.0647 of 5 stars$1.03-7.2%$4.67+353.1%-31.3%$26.11M$7.35M-1.0860Analyst ForecastGap DownNAIINatural Alternatives InternationalN/A$4.21-2.1%N/A-37.1%$26.10M$112.98M-2.99290Analyst ForecastENLVEnlivex Therapeutics2.3234 of 5 stars$1.17-2.5%$9.50+712.0%-36.6%$25.05MN/A0.0070LSBLakeshore Biopharma0.5004 of 5 stars$2.69+8.0%N/AN/A$25.04M$80.82M0.00773News CoverageGap UpEQEquillium2.9048 of 5 stars$0.68-2.8%$5.00+630.0%-16.5%$24.27M$45.91M-5.0440Gap DownSNTISenti Biosciences2.3435 of 5 stars$5.24-5.9%$10.00+90.8%-5.2%$24.05M$2.56M-0.334News CoverageGap UpAKTXAkari TherapeuticsN/A$0.97-0.3%N/A-67.2%$24.02MN/A0.009Analyst ForecastGap DownHigh Trading VolumeCMMBChemomab Therapeutics3.3163 of 5 stars$1.65+4.4%$7.33+344.4%+230.1%$23.69MN/A-1.5820Positive News Related Companies and Tools Related Companies Lipocine Competitors Pluri Competitors LAVA Therapeutics Competitors Natural Alternatives International Competitors Enlivex Therapeutics Competitors Lakeshore Biopharma Competitors Equillium Competitors Senti Biosciences Competitors Akari Therapeutics Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLTO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLTO Stock Alerts